It's normal for biotechs to buy intellectual property. It can be risky for a company to underinvest in its own R&D capabilities. 10 stocks we like better than Summit Therapeutics › For most of the ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Adecto Pharmaceuticals’ 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop. | Adecto Pharmaceuticals’ 12-year story has come ...

GATC Health has launched a new AI-driven platform designed to help biotech companies, investors, and insurers assess the risk of drug candidates before entering clinical trials. The tool, called ...

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

A little?known Warsaw-listed biotech just posted fresh data and a new cash runway. Here is why Captor Therapeutics is suddenly on global watchlists—and what US investors need to weigh before jumping ...